List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7383981/publications.pdf Version: 2024-02-01



FLENA ADRELO

#	Article	IF	CITATIONS
1	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	2.2	5,583
2	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
3	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2021, 42, 3427-3520.	2.2	899
4	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
5	2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 655-720.	2.2	647
6	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace, 2022, 24, 71-164.	1.7	370
7	Present Status of Brugada Syndrome. Journal of the American College of Cardiology, 2018, 72, 1046-1059.	2.8	291
8	Scar Dechanneling. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 326-336.	4.8	200
9	Combined Endocardial and Epicardial Catheter Ablation in Arrhythmogenic Right Ventricular Dysplasia Incorporating Scar Dechanneling Technique. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 111-121.	4.8	189
10	The Atrial Fibrillation Ablation Pilot Study: an European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. European Heart Journal, 2014, 35, 1466-1478.	2.2	180
11	Noninvasive Identification of Ventricular Tachycardia-Related Conducting Channels Using Contrast-Enhanced Magnetic Resonance Imaging in Patients With Chronic Myocardial Infarction. Journal of the American College of Cardiology, 2011, 57, 184-194.	2.8	173
12	SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. Heart Rhythm, 2020, 17, 1456-1462.	0.7	162
13	Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. European Heart Journal, 2017, 38, ehw564.	2.2	151
14	CMR-Guided Approach to Localize and Ablate Gaps in Repeat AF Ablation Procedure. JACC: Cardiovascular Imaging, 2014, 7, 653-663.	5.3	129
15	Left Atrial Sphericity: A New Method to Assess Atrial Remodeling. Impact on the Outcome of Atrial Fibrillation Ablation. Journal of Cardiovascular Electrophysiology, 2013, 24, 752-759.	1.7	127
16	ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. Europace, 2012, 14, 1094-1103.	1.7	123
17	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up. European Heart Journal, 2022, 43, 1059-1103.	2.2	111
18	Left atrial fibrosis quantification by late gadolinium-enhanced magnetic resonance: a new method to standardize the thresholds for reproducibility. Europace, 2017, 19, 1272-1279.	1.7	103

#	Article	IF	CITATIONS
19	Brugada syndrome: clinical and genetic findings. Genetics in Medicine, 2016, 18, 3-12.	2.4	102
20	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. Circulation, 2020, 142, 324-338.	1.6	83
21	Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. European Heart Journal, 2020, 41, 3437-3447.	2.2	78
22	Fever-related arrhythmic events in the multicenter Survey on Arrhythmic Events in Brugada Syndrome. Heart Rhythm, 2018, 15, 1394-1401.	0.7	71
23	Cryoballoon vs. radiofrequency ablation for atrial fibrillation: a study of outcome and safety based on the ESC-EHRA atrial fibrillation ablation long-term registry and the Swedish catheter ablation registry. Europace, 2019, 21, 581-589.	1.7	69
24	Monomorphic ventricular tachycardia in patients with Brugada syndrome: A multicenter retrospective study. Heart Rhythm, 2016, 13, 669-682.	0.7	67
25	Impact of body mass index on the outcome of catheter ablation of atrial fibrillation. Heart, 2019, 105, 244-250.	2.9	67
26	Gender differences in patients with Brugada syndrome and arrhythmic events: Data from a survey on arrhythmic events in 678 patients. Heart Rhythm, 2018, 15, 1457-1465.	0.7	65
27	Improvement of Reverse RemodelingÂUsing Electrocardiogram Fusion-Optimized Intervals in CardiacÂResynchronization Therapy. JACC: Clinical Electrophysiology, 2018, 4, 181-189.	3.2	64
28	Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace, 2021, 23, 494-495.	1.7	64
29	Natural and Undetermined Sudden Death: Value of Post-Mortem Genetic Investigation. PLoS ONE, 2016, 11, e0167358.	2.5	62
30	Recent Advances in Short QT Syndrome. Frontiers in Cardiovascular Medicine, 2018, 5, 149.	2.4	60
31	<scp>EAARN</scp> score, a predictive score for mortality in patients receiving cardiac resynchronization therapy based on preâ€implantation risk factors. European Journal of Heart Failure, 2014, 16, 802-809.	7.1	59
32	Fusionâ€Optimized Intervals (FOI): A New Method to Achieve the Narrowest QRS for Optimization of the AV and VV Intervals in Patients Undergoing Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2014, 25, 283-292.	1.7	58
33	Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation. International Journal of Cardiology, 2013, 168, 4093-4097.	1.7	57
34	Substrate modification or ventricular tachycardia induction, mapping, and ablation as the first step? A randomized study. Heart Rhythm, 2016, 13, 1589-1595.	0.7	57
35	Age of First Arrhythmic Event in Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	57
36	Profile of patients with Brugada syndrome presenting with their first documented arrhythmic event: Data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). Heart Rhythm, 2018, 15, 716-724.	0.7	57

#	Article	IF	CITATIONS
37	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. Genetics in Medicine, 2021, 23, 47-58.	2.4	57
38	Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. Nature Genetics, 2022, 54, 232-239.	21.4	55
39	Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome. Journal of the American College of Cardiology, 2019, 73, 1756-1765.	2.8	53
40	Accuracy of left atrial fibrosis detection with cardiac magnetic resonance: correlation of late gadolinium enhancement with endocardial voltage and conduction velocity. Europace, 2021, 23, 380-388.	1.7	52
41	Occupational radiation exposure in the electrophysiology laboratory with a focus on personnel with reproductive potential and during pregnancy: A European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS). Europace, 2017, 19, 1909-1922.	1.7	50
42	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. European Heart Journal, 2020, 41, 1132-1140.	2.2	50
43	Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study. Lancet, The, 2019, 394, 1344-1351.	13.7	49
44	Electrocardiographic versus Echocardiographic Optimization of the Interventricular Pacing Delay in Patients Undergoing Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2011, 22, 1129-1134.	1.7	48
45	Preferential regional distribution of atrial fibrosis in posterior wall around left inferior pulmonary vein as identified by late gadolinium enhancement cardiac magnetic resonance in patients with atrial fibrillation. Europace, 2018, 20, 1959-1965.	1.7	47
46	Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2: ventricular arrhythmias, channelopathies, and implantable defibrillators. Europace, 2021, 23, 147-148.	1.7	47
47	Reanalysis and reclassification of rare genetic variants associated with inherited arrhythmogenic syndromes. EBioMedicine, 2020, 54, 102732.	6.1	46
48	Ablation of Ventricular Arrhythmias in Arrhythmogenic Right Ventricular Dysplasia. Journal of Cardiovascular Electrophysiology, 2010, 21, 473-486.	1.7	45
49	Sinus rhythm detection of conducting channels and ventricular tachycardia isthmus in arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm, 2014, 11, 747-754.	0.7	44
50	Magnetic Resonance Imaging-Guided Fibrosis Ablation for the Treatment of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008707.	4.8	44
51	A Genetically Vulnerable Myocardium May Predispose to Myocarditis. Journal of the American College of Cardiology, 2015, 66, 2913-2914.	2.8	41
52	Long-term prognosis of patients with life-threatening ventricular arrhythmias induced by coronary artery spasm. Europace, 2018, 20, 851-858.	1.7	39
53	World Heart Federation Roadmap on Atrial Fibrillation – A 2020 Update. Global Heart, 2021, 16, 41.	2.3	39
54	Benefit of Left Atrial Roof Linear Ablation in Paroxysmal Atrial Fibrillation: A Prospective, Randomized Study. Journal of the American Heart Association, 2014, 3, e000877.	3.7	37

#	Article	IF	CITATIONS
55	HRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic. Journal of the American College of Cardiology, 2020, 76, 1363-1374.	2.8	37
56	Update on Genetic Basis of Brugada Syndrome: Monogenic, Polygenic or Oligogenic?. International Journal of Molecular Sciences, 2020, 21, 7155.	4.1	36
57	Patients With Brugada Syndrome and Implanted Cardioverter-Defibrillators. Journal of the American College of Cardiology, 2017, 70, 1991-2002.	2.8	34
58	Out-of-hospital cardiac arrest due to idiopathic ventricular fibrillation in patients with normal electrocardiograms: results from a multicentre long-term registry. Europace, 2019, 21, 1670-1677.	1.7	34
59	A missense mutation in the sodium channel \hat{l}^21b subunit reveals SCN1B as a susceptibility gene underlying long QT syndrome. Heart Rhythm, 2014, 11, 1202-1209.	0.7	33
60	Short QT Syndrome: A Comprehensive Genetic Interpretation and Clinical Translation of Rare Variants. Journal of Clinical Medicine, 2019, 8, 1035.	2.4	33
61	In-hospital and 12-month follow-up outcome from the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry: sex differences. Europace, 2020, 22, 66-73.	1.7	33
62	A QRS axis–based algorithm to identify the origin of scar-related ventricular tachycardia in the 17-segment American Heart Association model. Heart Rhythm, 2018, 15, 1491-1497.	0.7	32
63	Genetic interpretation and clinical translation of minor genes related to Brugada syndrome. Human Mutation, 2019, 40, 749-764.	2.5	32
64	HRS/EHRA/APHRS/LAHRS/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. Europace, 2021, 23, 313-313.	1.7	32
65	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up. Cardiovascular Research, 2022, 118, 1618-1666.	3.8	32
66	Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator. European Heart Journal, 2022, 43, 3041-3052.	2.2	32
67	Reproducibility and accuracy of late gadolinium enhancement cardiac magnetic resonance measurements for the detection of left atrial fibrosis in patients undergoing atrial fibrillation ablation procedures. Europace, 2019, 21, 724-731.	1.7	31
68	Scar channels in cardiac magnetic resonance to predict appropriate therapies in primary prevention. Heart Rhythm, 2021, 18, 1336-1343.	0.7	30
69	Bone Mass, Bone Turnover, Vitamin D, and Estrogen Receptor Gene Polymorphisms in Male to Female Transsexuals. Journal of Clinical Densitometry, 2003, 6, 297-304.	1.2	28
70	Mapping Data Predictors of a Left Ventricular Outflow Tract Origin of Idiopathic Ventricular Tachycardia With V ₃ Transition and Septal Earliest Activation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 484-491.	4.8	28
71	Evolución de la mejora en los resultados y las complicaciones de la ablación por catéter de la fibrilación auricular: aprendizaje, técnicas y metodologÃa. Revista Espanola De Cardiologia, 2012, 65, 131-138.	1.2	28
72	Delayed Gadolinium Enhancement Magnetic Resonance Imaging Detected Anatomic Gap Length in Wide Circumferential Pulmonary Vein Ablation Lesions Is Associated With Recurrence of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006659.	4.8	28

#	Article	IF	CITATIONS
73	Ventricular scar channel entrances identified by new wideband cardiac magnetic resonance sequence to guide ventricular tachycardia ablation in patients with cardiac defibrillators. Europace, 2020, 22, 598-606.	1.7	28
74	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis. Cardiovascular Research, 2022, 118, 1385-1412.	3.8	27
75	Role of copy number variants in sudden cardiac death and related diseases: genetic analysis and translation into clinical practice. European Journal of Human Genetics, 2018, 26, 1014-1025.	2.8	26
76	Reduction in new cardiac electronic device implantations in Catalonia during COVID-19. Europace, 2021, 23, 456-463.	1.7	25
77	European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology. European lournal of Preventive Cardiology. 2022. 29. 1060-1071.	1.8	25
78	Serum lipids and estrogen receptor gene polymorphisms in male-to-female transsexuals: effects of estrogen treatment. European Journal of Internal Medicine, 2004, 15, 231-237.	2.2	23
79	Reversal of spherical remodelling of the left atrium after pulmonary vein isolation: incidence and predictors. Europace, 2014, 16, 840-847.	1.7	23
80	Large Genomic Imbalances in Brugada Syndrome. PLoS ONE, 2016, 11, e0163514.	2.5	23
81	Stop-Gain Mutations in PKP2 Are Associated with a Later Age of Onset of Arrhythmogenic Right Ventricular Cardiomyopathy. PLoS ONE, 2014, 9, e100560.	2.5	22
82	The longâ€QT syndrome and exercise practice: The neverâ€ending debate. Journal of Cardiovascular Electrophysiology, 2018, 29, 489-496.	1.7	22
83	Ethnic differences in patients with Brugada syndrome and arrhythmic events: New insights from Survey on Arrhythmic Events in Brugada Syndrome. Heart Rhythm, 2019, 16, 1468-1474.	0.7	22
84	SCN5A mutation type and topology are associated with the risk of ventricular arrhythmia by sodium channel blockers. International Journal of Cardiology, 2018, 266, 128-132.	1.7	21
85	Complete atrioventricular block does not reduce longâ€ŧerm mortality in patients with permanent atrial fibrillation treated with cardiac resynchronization therapy. European Journal of Heart Failure, 2013, 15, 1412-1418.	7.1	20
86	HRS/EHRA/APHRS/LAHRS/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. Heart Rhythm, 2020, 17, e255-e268.	0.7	20
87	Sudden Cardiac Death and Copy Number Variants: What Do We Know after 10 Years of Genetic Analysis?. Forensic Science International: Genetics, 2020, 47, 102281.	3.1	20
88	Ventricular tachycardia burden reduction after substrate ablation: Predictors of recurrence. Heart Rhythm, 2021, 18, 896-904.	0.7	20
89	European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. Europace, 2022, 24, 165-172.	1.7	20
90	T-Wave Oversensing in Patients With Brugada Syndrome: True Bipolar Versus Integrated Bipolar Implantable Cardioverter Defibrillator Leads. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 792-798.	4.8	19

#	Article	IF	CITATIONS
91	Sequenom MassARRAY approach in the arrhythmogenic right ventricular cardiomyopathy post-mortem setting: clinical and forensic implications. International Journal of Legal Medicine, 2015, 129, 1-10.	2.2	18
92	â€~Real-world' observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). Europace, 2020, 22, 831-832.	1.7	18
93	Magnetic resonance-guided re-ablation for atrial fibrillation is associated with a lower recurrence rate: a case–control study. Europace, 2020, 22, 1805-1811.	1.7	18
94	Outcomes of conduction system pacing compared to right ventricular pacing as a primary strategy for treating bradyarrhythmia: systematic review and meta-analysis. Clinical Research in Cardiology, 2022, 111, 1198-1209.	3.3	18
95	Risk Stratification and Treatment of Brugada Syndrome. Current Cardiology Reports, 2014, 16, 508.	2.9	16
96	Genetic analysis, in silico prediction, and family segregation in long QT syndrome. European Journal of Human Genetics, 2015, 23, 79-85.	2.8	16
97	Brugada Syndrome and Exercise Practice: Current Knowledge, Shortcomings and Open Questions. International Journal of Sports Medicine, 2017, 38, 573-581.	1.7	16
98	Time-to-first appropriate shock in patients implanted prophylactically with an implantable cardioverter-defibrillator: data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). Europace, 2019, 21, 796-802.	1.7	16
99	The arrhythmogenic right ventricular cardiomyopathy in comparison to the athletic heart. Journal of Cardiovascular Electrophysiology, 2020, 31, 1836-1843.	1.7	16
100	Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 229-237.	4.0	16
101	Postprocedural LGEâ€CMR comparison of laser and radiofrequency ablation lesions after pulmonary vein isolation. Journal of Cardiovascular Electrophysiology, 2018, 29, 1065-1072.	1.7	15
102	Influence of risk factors in the ESCâ€EHRA EORP atrial fibrillation ablation longâ€ŧerm registry. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1365-1373.	1.2	15
103	Electrocardiographic optimization techniques in resynchronization therapy. Europace, 2019, 21, 1286-1296.	1.7	15
104	The role of clinical assessment and electrophysiology study in Brugada syndrome patients with syncope. American Heart Journal, 2020, 220, 213-223.	2.7	15
105	HRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e009007.	4.8	15
106	Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine. European Heart Journal, 2020, 41, 614-617.	2.2	15
107	Clinical interpretation of genetic variants in arrhythmogenic right ventricular cardiomyopathy. Clinical Research in Cardiology, 2015, 104, 288-303.	3.3	13
108	Regional differences in referral, procedures, and outcome after ablation for atrial fibrillation in Europe: a report from the Atrial Fibrillation Ablation Pilot Registry of the European Society of Cardiology. Europace, 2016, 18, 191-200.	1.7	13

#	Article	IF	CITATIONS
109	Rare Variants Associated with Arrhythmogenic Cardiomyopathy: Reclassification Five Years Later. Journal of Personalized Medicine, 2021, 11, 162.	2.5	13
110	Long-term prognosis of women with Brugada syndrome and electrophysiological study. Heart Rhythm, 2021, 18, 664-671.	0.7	13
111	Prevalence of Pathogenic Variants in Cardiomyopathy-Associated Genes in Myocarditis. Circulation Genomic and Precision Medicine, 2022, 15, 101161CIRCGEN121003408.	3.6	13
112	Plasma tissue inhibitor of matrix metalloproteinase-1 a predictor of long-term mortality in patients treated with cardiac resynchronization therapy. Europace, 2016, 18, 232-237.	1.7	12
113	Management of anticoagulation in patients undergoing leadless pacemaker implantation. Heart Rhythm, 2019, 16, 1849-1854.	0.7	12
114	COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias. Heart Rhythm, 2020, 17, 1423-1424.	0.7	12
115	Cardiac magnetic resonance to predict recurrences after ventricular tachycardia ablation: septal involvement, transmural channels, and left ventricular mass. Europace, 2021, 23, 1437-1445.	1.7	12
116	Sport practice in hypertrophic cardiomyopathy: running to stand still?. International Journal of Cardiology, 2021, 345, 77-82.	1.7	12
117	Improved Outcomes and Complications of Atrial Fibrillation Catheter Ablation Over Time: Learning Curve, Techniques, and Methodology. Revista Espanola De Cardiologia (English Ed), 2012, 65, 131-138.	0.6	11
118	Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. Europace, 2019, 21, 1802-1808.	1.7	11
119	Cryoballoon vs. radiofrequency lesions as detected by late-enhancement cardiac magnetic resonance after ablation of paroxysmal atrial fibrillation: a case–control study. Europace, 2020, 22, 382-387.	1.7	11
120	Ablation strategies for different types of atrial fibrillation in Europe: results of the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry. Europace, 2020, 22, 558-566.	1.7	11
121	Clinical impact of rare variants associated with inherited channelopathies: a 5-year update. Human Genetics, 2022, 141, 1579-1589.	3.8	11
122	Genetics of inherited arrhythmias in pediatrics. Current Opinion in Pediatrics, 2015, 27, 665-674.	2.0	10
123	Late gadolinium enhancementâ€MRI determines definite lesion formation most accurately at 3 months post ablation compared to later time points. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 72-82.	1.2	10
124	Successful slow pathway ablation for atrioventricular nodal re-entrant tachycardia via a hypoplastic inferior vena cava in a patient with an azygos continuation. Europace, 2008, 10, 467-468.	1.7	9
125	Atrial fibrillation history impact on catheter ablation outcome. Findings from the ESCâ€EHRA Atrial Fibrillation Ablation Longâ€Term Registry. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 313-320.	1.2	9
126	Proximity to the descending aorta predicts regional fibrosis in the adjacent left atrial wall: aetiopathogenic and prognostic implications. Europace, 2021, 23, 1559-1567.	1.7	9

#	Article	IF	CITATIONS
127	Clinical Genetics of Inherited Arrhythmogenic Disease in the Pediatric Population. Biomedicines, 2022, 10, 106.	3.2	9
128	Ultrasound Findings During Percutaneous Treatment of Bifurcated Coronary Lesions. Revista Espanola De Cardiologia (English Ed), 2008, 61, 930-935.	0.6	7
129	Long-term benefit of first-line peri-implantable cardioverter–defibrillator implant ventricular tachycardia-substrate ablation in secondary prevention patients. Europace, 2016, 19, euw096.	1.7	7
130	Which patients with atrial fibrillation undergo an ablation procedure today in Europe? A report from the ESC-EHRA-EORP Atrial Fibrillation Ablation Long-Term and Atrial Fibrillation General Pilot Registries. Europace, 2020, 22, 250-258.	1.7	7
131	Genotype-Phenotype Correlation of <i>SCN5A</i> Genotype in Patients With Brugada Syndrome and Arrhythmic Events: Insights From the SABRUS in 392 Probands. Circulation Genomic and Precision Medicine, 2021, 14, e003222.	3.6	7
132	The prevalence of left and right bundle branch block morphology ventricular tachycardia amongst patients with arrhythmogenic cardiomyopathy and sustained ventricular tachycardia: insights from the European Survey on Arrhythmogenic Cardiomyopathy. Europace, 2022, 24, 285-295.	1.7	7
133	Conduction system pacing vs. biventricular pacing in patients with ventricular dysfunction and AV block. PACE - Pacing and Clinical Electrophysiology, 2022, , .	1.2	7
134	Gene-Specific Therapy for Congenital Long QT Syndrome. Journal of the American College of Cardiology, 2016, 67, 1059-1061.	2.8	6
135	Personalized Interpretation and Clinical Translation of Genetic Variants Associated With Cardiomyopathies. Frontiers in Genetics, 2019, 10, 450.	2.3	6
136	Impact of centre volume on atrial fibrillation ablation outcomes in Europe: a report from the ESC EHRA EORP Atrial Fibrillation Ablation Long-Term (AFA LT) Registry. Europace, 2021, 23, 49-58.	1.7	6
137	The 2020 ESC atrial fibrillation guidelines for atrial fibrillation catheter ablation, CABANA, and EAST. Europace, 2022, 24, ii3-ii7.	1.7	6
138	Late Potential Abolition in Ventricular Tachycardia Ablation. American Journal of Cardiology, 2022, 174, 53-60.	1.6	6
139	Impact of SARSâ€Covâ€2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. ESC Heart Failure, 2022, 9, 2189-2198.	3.1	6
140	Personalized Remote Monitoring of the Atrial Fibrillation Patients with Electronic Implant Devices. Journal of Healthcare Engineering, 2011, 2, 183-196.	1.9	5
141	CardioPulse Articles. European Heart Journal, 2011, 32, 1173-1181.	2.2	5
142	Inappropriate ICD Shocks - When Monitoring Zones Do More Than Monitor. Indian Pacing and Electrophysiology Journal, 2013, 13, 190-193.	0.6	5
143	Genetic Variants as Sudden-Death Risk Markers in Inherited Arrhythmogenic Syndromes: Personalized Genetic Interpretation. Journal of Clinical Medicine, 2020, 9, 1866.	2.4	5
144	Q waves are the strongest electrocardiographic variable associated with primary prophylactic implantable cardioverter-defibrillator benefit: a prospective multicentre study. Europace, 2022, 24, 774-783.	1.7	5

#	Article	IF	CITATIONS
145	Electrocardiographic Assessment and Genetic Analysis in Neonates: a Current Topic of Discussion. Current Cardiology Reviews, 2018, 15, 30-37.	1.5	5
146	Accuracy of standard bipolar amplitude voltage thresholds to identify late potential channels in ventricular tachycardia ablation. Journal of Interventional Cardiac Electrophysiology, 2023, 66, 15-25.	1.3	5
147	Brugada Syndrome in Women: What Do We Know After 30 Years?. Frontiers in Cardiovascular Medicine, 2022, 9, 874992.	2.4	5
148	Double-Wire Technique for Implanting a Left Ventricular Venous Lead in Patients With Complicated Coronary Venous Anatomy. Revista Espanola De Cardiologia (English Ed), 2007, 60, 110-116.	0.6	4
149	Guideline-driven telemonitoring and follow-up of cardiovascular implantable electronic devices using IEEE 11073, HL7 & IHE profiles. , 2011, 2011, 3192-6.		4
150	Malignant Arrhythmogenic Role Associated with RBM20: A Comprehensive Interpretation Focused on a Personalized Approach. Journal of Personalized Medicine, 2021, 11, 130.	2.5	4
151	Septal flash correction with Hisâ€Purkinje pacing predicts echocardiographic response in resynchronization therapy. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 374-383.	1.2	4
152	Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association. European Journal of Heart Failure, 2019, 21, 690-693.	7.1	3
153	Electromechanical delay by speckle-tracking echocardiography: A novel tool to distinguish between Brugada syndrome and isolated right bundle branch block. International Journal of Cardiology, 2020, 320, 161-167.	1.7	3
154	Pediatric Malignant Arrhythmias Caused by Rare Homozygous Genetic Variants in TRDN: A Comprehensive Interpretation. Frontiers in Pediatrics, 2020, 8, 601708.	1.9	3
155	Early Identification of Prolonged QT Interval for Prevention of Sudden Infant Death. Frontiers in Pediatrics, 2021, 9, 704580.	1.9	3
156	Usefulness of Hyperemic Venous Return Angiography for Studying Coronary Venous Anatomy Prior to Cardiac Resynchronization Device Implantation. Revista Espanola De Cardiologia (English Ed), 2008, 61, 936-944.	0.6	2
157	Late Failure of Left Ventricular Leads Stabilized Using the Retained Guidewire Technique in Patients Undergoing Cardiac Resynchronization Therapy. Revista Espanola De Cardiologia (English Ed), 2008, 61, 91-94.	0.6	2
158	Left Atrial Tachycardia After Atrial Fibrillation Ablation: Can Magnetic Resonance Imaging Assist the Ablation?. Canadian Journal of Cardiology, 2015, 31, 104.e1-104.e3.	1.7	2
159	Ventricular Fibrillation Inducibility in the Early Repolarization Syndrome. Journal of the American College of Cardiology, 2015, 65, 160-162.	2.8	2
160	European Heart Rhythm Association Young Electrophysiology Community: the future is just ahead. Europace, 2016, 18, 785-787.	1.7	2
161	Optimized singleâ€point left ventricular pacing leads to improved resynchronization compared with multipoint pacing. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 519-527.	1.2	2
162	Cardiac Resynchronization Therapy Response Is Equalized in Men and Women byÂElectricalÂOptimization. JACC: Clinical Electrophysiology, 2021, 7, 1400-1409.	3.2	2

#	Article	IF	CITATIONS
163	Atrial fibrillation ablation in heart failure: Findings from the ESC-EHRA EORP Atrial Fibrillation Ablation long-term (AFA LT) registry. International Journal of Cardiology, 2022, 346, 19-26.	1.7	2
164	Discerning the Ambiguous Role of Missense TTN Variants in Inherited Arrhythmogenic Syndromes. Journal of Personalized Medicine, 2022, 12, 241.	2.5	2
165	Status of cardiac resynchronization therapy in Catalonia, Spain: Results of the prospective multicentric study TRC-CAT. Medicina ClÂnica (English Edition), 2016, 146, 423-428.	0.2	1
166	Another piece of the puzzle: Assessment of mechanical dispersion by magnetic resonance in long QT syndrome. Heart Rhythm, 2017, 14, 1398-1399.	0.7	1
167	Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative) Tj ETQq1 1 0.78	4314 rgBT 0.9	/Overlock 1 1
168	Failure-free survival of the Riata implantable cardioverter-defibrillator lead after a very long-term follow-up. Indian Pacing and Electrophysiology Journal, 2019, 19, 140-144.	0.6	1
169	Adenosine usage during AF ablation in Europe and selected long-term findings from the ESC-EHRA EORP Atrial Fibrillation Ablation Long-Term registry. Journal of Interventional Cardiac Electrophysiology, 2021, 60, 395-406.	1.3	1
170	Validation of multiparametric approaches for the prediction of sudden cardiac death in patients with Brugada syndrome and electrophysiological study. Revista Espanola De Cardiologia (English Ed), 2021, , .	0.6	1
171	<i>BAG3</i> Genetic Cardiomyopathy May Overlap Fulminant Myocarditis Clinical Findings. Circulation: Heart Failure, 2022, 15, e008443.	3.9	1
172	Rapid palpitations: three of a kind?. Netherlands Heart Journal, 2013, 21, 472-472.	0.8	0
173	Cardiac Rhythm Management Devices. Journal of the American College of Cardiology, 2014, 63, 1776-1777.	2.8	0
174	Reply to the Editor—Electrophysiologic study in women with Brugada Syndrome. Heart Rhythm, 2021, 18, 1039-1040.	0.7	0
175	Implantable Loop Recorders in Brugada syndrome: an ally?. Heart Rhythm, 2021, , .	0.7	0
176	Update on the Differential Diagnosis and Treatment of Brugada Syndrome. , 2016, , 139-172.		0
177	Brugada syndrome, Brugada phenocopy, or simply arrythmia induced by cocaine intoxication?. Emergencias, 2020, 32, 72-74.	0.6	0